Bruker outlines 15-17% EPS growth and targets 250-300 bps margin expansion for 2026 amid cost initiatives and market recovery
Source: SeekingAlpha
2026-02-12 13:35:18 ET
More on Bruker
- Bruker Corporation (BRKR) Q4 2025 Earnings Call Transcript
- Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Bruker reports mixed Q4 results; initiates FY26 outlook
- Bruker Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Bruker outlines 15–17% EPS growth and targets 250–300 bps margin expansion for 2026 amid cost initiatives and market recovery
Bruker Corporation
NASDAQ: BRKR
BRKR Trading
-2.36% G/L:
$36.54 Last:
655,723 Volume:
$36.33 Open:
BRKR Latest News
February 25, 2026 07:00:00 am
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
February 24, 2026 07:00:00 am
Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications
BRKR Stock Data
$6,342,783,056
108,941,800
0.01%
138
N/A
Biotechnology & Life Sciences
Healthcare
US
Billerica
